{
    "data": [
        {
            "id": "4314636",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-31T04:46:00-05:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "My 'Fallen Angels' Favorites For 2020: Pfizer, No. 3 Of 3",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21428",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "251193",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4314636-fallen-angels-favorites-for-2020-pfizer-no-3-of-3"
            }
        },
        {
            "id": "4312913",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-17T11:27:59-05:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: New CEO, New Strategy, New Focus On Brand Name Drugs In A Year Of Drastic Change",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31111",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "247882",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4312913-pfizer-new-ceo-new-strategy-new-focus-on-brand-name-drugs-in-year-of-drastic-change"
            }
        },
        {
            "id": "4312824",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-16T19:16:23-05:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: A New Science-Based Pharma Wonder",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "88056",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "247549",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4312824-pfizer-new-science-based-pharma-wonder"
            }
        },
        {
            "id": "4310396",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-03T21:18:29-05:00",
                "isLockedPro": false,
                "commentCount": 61,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Oxbryta Is Aimed For Success",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "244880",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4310396-global-blood-therapeutics-oxbryta-is-aimed-for-success"
            }
        },
        {
            "id": "4310122",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-02T14:37:55-05:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood: Beware Of This Key Investment Risk As Voxelotor Enters Commercialization",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104483",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "79239",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4310122-global-blood-beware-of-this-key-investment-risk-voxelotor-enters-commercialization"
            }
        },
        {
            "id": "4309374",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-27T04:22:32-05:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Oxbryta Is Finally Approved",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "243610",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4309374-global-blood-therapeutics-oxbryta-is-finally-approved"
            }
        },
        {
            "id": "4309264",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-26T13:57:22-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: FDA Approval Of Oxbryta Moves Company Into A Large Market Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "243505",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4309264-global-blood-therapeutics-fda-approval-of-oxbryta-moves-company-large-market-opportunity"
            }
        },
        {
            "id": "4309204",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-26T11:07:26-05:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Grab The Popcorn, Wait And See",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "243141",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4309204-pfizer-grab-popcorn-wait-and-see"
            }
        },
        {
            "id": "4299719",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-28T18:47:18-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Latest Data For JAK Inhibitor Drug Lines It Up To Take On Rivals",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "77298",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4299719-pfizers-latest-data-for-jak-inhibitor-drug-lines-up-to-take-on-rivals"
            }
        },
        {
            "id": "4298147",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-23T09:03:44-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Expectations Swell As Voxelotor Marketization Nears",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "75932",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4298147-global-blood-therapeutics-expectations-swell-voxelotor-marketization-nears"
            }
        },
        {
            "id": "4297723",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-21T19:34:27-04:00",
                "isLockedPro": false,
                "commentCount": 75,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Avoid This High Yield",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "75661",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4297723-pfizer-avoid-this-high-yield"
            }
        },
        {
            "id": "4296481",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-14T15:43:23-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: A Core Biotech Buy For Patient Investors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24589",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "74113",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4296481-global-blood-therapeutics-core-biotech-buy-for-patient-investors"
            }
        },
        {
            "id": "4296171",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-11T17:24:11-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Push For Antisense Licensing Is Closely Aligned With Current Target Indications",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "73646",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4296171-pfizers-push-for-antisense-licensing-is-closely-aligned-current-target-indications"
            }
        },
        {
            "id": "4293615",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-26T04:22:31-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Recent Dip Presents Buying Opportunity In Arena Pharmaceuticals",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20510",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "70242",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4293615-recent-dip-presents-buying-opportunity-in-arena-pharmaceuticals"
            }
        },
        {
            "id": "4291292",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-13T10:45:04-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Looks To Expand Market Opportunity For Its Blockbuster Drug Xtandi",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "66601",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4291292-pfizer-looks-to-expand-market-opportunity-for-blockbuster-drug-xtandi"
            }
        },
        {
            "id": "4290440",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-09T03:40:25-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Stock Responds To Voxelotor Receiving Priority Review",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104805",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "65680",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4290440-global-blood-therapeutics-stock-responds-to-voxelotor-receiving-priority-review"
            }
        },
        {
            "id": "4285036",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-13T04:04:31-04:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merger Talk Boosts Pfizer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103687",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "59719",
                            "type": "sentiment"
                        },
                        {
                            "id": "59718",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4285036-merger-talk-boosts-pfizer"
            }
        },
        {
            "id": "4284829",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-12T11:03:38-04:00",
                "isLockedPro": false,
                "commentCount": 92,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Dividend Confusion Is Likely To Create Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24443",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "59104",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4284829-pfizers-dividend-confusion-is-likely-to-create-opportunity"
            }
        },
        {
            "id": "4281921",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-06T02:47:28-04:00",
                "isLockedPro": false,
                "commentCount": 90,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "I'm Lowering My Fair Value Estimate For Pfizer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "57622",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4281921-lowering-fair-value-estimate-for-pfizer"
            }
        },
        {
            "id": "4281534",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-05T01:05:45-04:00",
                "isLockedPro": false,
                "commentCount": 46,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: A Defensive Dividend Stock Even After The Spin-Off",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103213",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "57158",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4281534-pfizer-defensive-dividend-stock-even-after-spin-off"
            }
        },
        {
            "id": "4280149",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-01T12:09:04-04:00",
                "isLockedPro": false,
                "commentCount": 139,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Might Cut Its Dividend: 3 Things Investors Need To Know",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "56645",
                            "type": "sentiment"
                        },
                        {
                            "id": "56646",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4280149-pfizer-might-cut-dividend-3-things-investors-need-to-know"
            }
        },
        {
            "id": "4279750",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-31T16:49:10-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan And Pfizer's Off-Patented Business: Tie-Up Of 2 Challenged Entities",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "56216",
                            "type": "sentiment"
                        },
                        {
                            "id": "56217",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4279750-mylan-and-pfizers-off-patented-business-tie-up-of-2-challenged-entities"
            }
        },
        {
            "id": "4278954",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-30T10:38:37-04:00",
                "isLockedPro": false,
                "commentCount": 86,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Understanding The Mylan-Upjohn Merger",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56062",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "55848",
                            "type": "sentiment"
                        },
                        {
                            "id": "55849",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4278954-understanding-mylan-upjohn-merger"
            }
        },
        {
            "id": "4278926",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-30T09:11:54-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Revisiting Global Blood Therapeutics",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "55580",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4278926-revisiting-global-blood-therapeutics"
            }
        },
        {
            "id": "4278741",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-29T15:11:28-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: A Promising Biotech Pick In 2019",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102293",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "55330",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4278741-global-blood-therapeutics-promising-biotech-pick-in-2019"
            }
        },
        {
            "id": "4278609",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-29T09:33:55-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Totality Of Voxelotor Phase 3 Data Increases My Conviction In Global Blood Therapeutics",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "55552",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4278609-totality-of-voxelotor-phase-3-data-increases-conviction-in-global-blood-therapeutics"
            }
        },
        {
            "id": "4277571",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-25T13:00:18-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Continues To Build Its Long-Term Potential",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "50452",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "54918",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4277571-pfizer-continues-to-build-long-term-potential"
            }
        },
        {
            "id": "4273975",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-08T23:06:01-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: My 3 Reasons For A Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104805",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "50239",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4273975-global-blood-therapeutics-3-reasons-for-buy"
            }
        },
        {
            "id": "4273643",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-06T02:14:18-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Raining In The Desert With Voxelotor",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "50138",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4273643-global-blood-therapeutics-raining-in-desert-voxelotor"
            }
        },
        {
            "id": "4273635",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-05T20:25:28-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Remains A Strong Hold In Our Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "67113",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "50314",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4273635-pfizer-remains-strong-hold-in-portfolio"
            }
        },
        {
            "id": "4273292",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-03T09:11:26-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Voxelotor Can Take The Stock Price To New All-Time Highs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104855",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "49267",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4273292-global-blood-therapeutics-voxelotor-can-take-stock-price-to-new-all-time-highs"
            }
        },
        {
            "id": "4271909",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-24T20:50:16-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: This Blue Chip DGI Name Strengthens Its Pipeline With Array BioPharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "47496",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4271909-pfizer-this-blue-chip-dgi-name-strengthens-pipeline-array-biopharma"
            }
        },
        {
            "id": "4271817",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-24T12:04:22-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Array Deal Makes Sense",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101850",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "47205",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4271817-pfizer-array-deal-makes-sense"
            }
        },
        {
            "id": "4271453",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-21T09:23:49-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biotech Acquisition Prospects As Handicapped By Market-Makers",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23468",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "46419",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4271453-biotech-acquisition-prospects-handicapped-market-makers"
            }
        },
        {
            "id": "4270947",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-19T00:01:04-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer-Array Deal: Growth And Pipeline Addition",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "46399",
                            "type": "sentiment"
                        },
                        {
                            "id": "46264",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4270947-pfizer-array-deal-growth-and-pipeline-addition"
            }
        },
        {
            "id": "4270927",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-18T18:57:25-04:00",
                "isLockedPro": false,
                "commentCount": 55,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics' Data Falls On Deaf Ears, But Massive Potential Exists With Accelerated Approval Pathway",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "46267",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4270927-global-blood-therapeutics-data-falls-on-deaf-ears-massive-potential-exists-accelerated"
            }
        },
        {
            "id": "4270674",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-17T15:17:22-04:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Acquisition Of Array BioPharma: An Inevitable Deal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "45996",
                            "type": "sentiment"
                        },
                        {
                            "id": "45976",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4270674-pfizers-acquisition-of-array-biopharma-inevitable-deal"
            }
        },
        {
            "id": "4270285",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-14T11:15:35-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Hold Pfizer: A Market Performer For Income",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "85096",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "45063",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4270285-hold-pfizer-market-performer-for-income"
            }
        },
        {
            "id": "4269502",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-10T16:49:16-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Dividend Arbitrage For Pfizer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "86786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "44288",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4269502-dividend-arbitrage-for-pfizer"
            }
        },
        {
            "id": "4267133",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-29T16:46:13-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer And PF-05221304 In NASH: The Lead Clinical Asset",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104202",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "41478",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4267133-pfizer-and-pfminus-05221304-in-nash-lead-clinical-asset"
            }
        },
        {
            "id": "4266229",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-23T18:58:51-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Has Limited Downside",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "67113",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "40288",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4266229-pfizer-limited-downside"
            }
        },
        {
            "id": "4265943",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-22T20:35:33-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Posts Positive Phase 3 Study In Eczema, Several Other Clinical Products In Place",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "40039",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4265943-pfizer-posts-positive-phase-3-study-in-eczema-several-clinical-products-in-place"
            }
        },
        {
            "id": "4265581",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-21T14:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Added Value For A Defensive Pharma Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103071",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "39334",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4265581-pfizer-added-value-for-defensive-pharma-portfolio"
            }
        },
        {
            "id": "4265399",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-20T17:58:00-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Nabs Regulatory Approval For Tafamidis, An FDA First Is Achieved",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "39432",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4265399-pfizer-nabs-regulatory-approval-for-tafamidis-fda-first-is-achieved"
            }
        },
        {
            "id": "4265396",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-20T17:22:50-04:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: A 3.5% Yield, But Lyrica's Patent Loss Keeps Me From Buying",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20449",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "39115",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4265396-pfizer-3_5-percent-yield-lyricas-patent-loss-keeps-me-from-buying"
            }
        },
        {
            "id": "4264284",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-15T12:37:32-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Acquires Therachon, Looks To Add To Rare Disease Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "38131",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4264284-pfizer-acquires-therachon-looks-to-add-to-rare-disease-pipeline"
            }
        },
        {
            "id": "4264205",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-15T09:30:07-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Remains On Track For Transformational Year",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "36961",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4264205-global-blood-remains-on-track-for-transformational-year"
            }
        },
        {
            "id": "4263786",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-14T10:24:50-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena's Etrasimod Possesses Positive Attributes, But It Is Not Unique",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104563",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "37525",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4263786-arenas-etrasimod-possesses-positive-attributes-is-not-unique"
            }
        },
        {
            "id": "4253754",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-10T10:19:02-04:00",
                "isLockedPro": false,
                "commentCount": 44,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Solid, Stable Returns",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "29715",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4253754-pfizer-solid-stable-returns"
            }
        },
        {
            "id": "4250617",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-22T20:55:20-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Steps Further In The Door For Gene Therapies",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "25499",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4250617-pfizer-steps-in-door-for-gene-therapies"
            }
        },
        {
            "id": "4248546",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-13T16:48:03-04:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: This Biotech Blue-Chip Offers Market-Beating Total Return Potential",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104980",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "23023",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4248546-pfizer-this-biotech-blue-chip-offers-market-beating-total-return-potential"
            }
        },
        {
            "id": "4247023",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-07T13:46:42-05:00",
                "isLockedPro": false,
                "commentCount": 77,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena And MannKind Are Associated - Could Something Bigger Happen?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20510",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "10201",
                            "type": "sentiment"
                        },
                        {
                            "id": "10202",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4247023-arena-and-mannkind-are-associated-something-bigger-happen"
            }
        },
        {
            "id": "4246335",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-05T02:27:34-05:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "With $1.3 Billion In Cash, Arena Poised To Move",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20510",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "10125",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4246335-1_3-billion-in-cash-arena-poised-to-move"
            }
        },
        {
            "id": "4243756",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-25T05:13:33-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Street Bullish As Pfizer's Growth Is Set To Reaccelerate Beyond 2019",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "78545",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "9274",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4243756-street-bullish-pfizers-growth-is-set-to-reaccelerate-beyond-2019"
            }
        },
        {
            "id": "4241914",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-18T14:41:31-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer In NASH: Left Behind And The Desperate Refocus",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104202",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "8559",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4241914-pfizer-in-nash-left-behind-and-desperate-refocus"
            }
        },
        {
            "id": "4240332",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-12T16:33:20-05:00",
                "isLockedPro": false,
                "commentCount": 85,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "2 Dividend Blue-Chips Set To Soar And 1 You Should Ignore",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "7968",
                            "type": "sentiment"
                        },
                        {
                            "id": "7969",
                            "type": "sentiment"
                        },
                        {
                            "id": "7970",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4240332-2-dividend-blue-chips-set-to-soar-and-1-you-should-ignore"
            }
        },
        {
            "id": "4239451",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-08T11:52:53-05:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: A Crucial Year Ahead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "7536",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4239451-global-blood-therapeutics-crucial-year-ahead"
            }
        },
        {
            "id": "4238396",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-06T09:15:00-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Biopharmaceuticals Group's Late-Stage Pipeline Looks Well Positioned",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104999",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "7063",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4238396-pfizer-biopharmaceuticals-groups-late-stage-pipeline-looks-well-positioned"
            }
        },
        {
            "id": "4236695",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-30T12:59:23-05:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Strong Buy Heading Into 2019",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103541",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "6492",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4236695-pfizer-strong-buy-heading-2019"
            }
        },
        {
            "id": "4236122",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-28T21:29:29-05:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Investment Update And New Data Via Passionate-Use",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "6207",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4236122-global-blood-therapeutics-investment-update-and-new-data-via-passionate-use"
            }
        },
        {
            "id": "4235596",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-25T09:10:23-05:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena's Deal With United Therapeutics Passes Regulatory Hurdle",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20510",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "5990",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4235596-arenas-deal-united-therapeutics-passes-regulatory-hurdle"
            }
        },
        {
            "id": "4234835",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-22T17:31:28-05:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Still A Cash Cow",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "67113",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "5684",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4234835-pfizer-still-cash-cow"
            }
        },
        {
            "id": "4234704",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-22T11:27:05-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Looks To Move Tafamidis Forward With Priority Review",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "5573",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4234704-pfizer-looks-to-move-tafamidis-forward-priority-review"
            }
        },
        {
            "id": "4233354",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-14T20:43:58-05:00",
                "isLockedPro": false,
                "commentCount": 71,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics Continues To Build Strong Case For Successful Commercialization",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103416",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "4749",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4233354-global-blood-therapeutics-continues-to-build-strong-case-for-successful-commercialization"
            }
        },
        {
            "id": "4233183",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-14T10:26:30-05:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Amgen And Pfizer: 2 Healthcare Companies We Want To Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "98446",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "4637",
                            "type": "sentiment"
                        },
                        {
                            "id": "4638",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4233183-amgen-and-pfizer-2-healthcare-companies-want-to-buy"
            }
        },
        {
            "id": "4231712",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-07T03:22:41-05:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "GlaxoSmithKline / Pfizer Consumer Merger: Multiple Arbitrage, Synergies, And Focus",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104565",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "3940",
                            "type": "sentiment"
                        },
                        {
                            "id": "3941",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4231712-glaxosmithkline-pfizer-consumer-merger-multiple-arbitrage-synergies-and-focus"
            }
        }
    ]
}